Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • AYUSH
    • 732 complaints of...

    732 complaints of misleading advertisements regarding herbal medicines: Minister informs Parliament

    Written by Ruby Khatun Khatun Published On 2018-08-12T10:15:45+05:30  |  Updated On 16 Aug 2021 2:59 PM IST

    New Delhi: The Minister of State (Independent Charge) for AYUSH, Shri Shripad Yesso Naik in a written reply to a question in Rajya Sabha 732 complaints of misleading advertisements regarding herbal medicines have been reported in the period from 20th January 2017 to 19th January 2018.


    Ministry of AYUSH has been receiving written and online complaints of misleading advertisements of Ayush medicines including herbal medicines/products. Such complaints are also registered in the GAMA (Grievances Against Misleading Advertisements) portal maintained by the Department of Consumer Affairs (DoCA).


    About 809 complaints of advertisements pertaining to Ayush and herbal medicines/products have been received during the period from April 2015 to March 2018.


    Advertising Standards Council of India (ASCI), with whom Ministry had signed a MoU for suo moto monitoring of Ayush advertisements appearing in print and TV media, reported 732 complaints in the period from 20th January 2017 to 19th January 2018.


    Six states/UTs including Delhi, Maharashtra, Gujarat, Kerala, Karnataka and Chandigarh have reported 573 instances of such misleading advertisement during the last three years.


    The provisions of Rule 158-B of the Drugs & Cosmetics Rules, 1945 provide for pilot studies for generating proof of safety and effectiveness for grant of the license to manufacture for sale certain categories of Ayurveda, Siddha, and Unani drugs. As such the terms 'herbal medicines' and 'clinical trials' are not provided or prescribed in the provisions of Drugs and Cosmetics Act, 1940 and Rules thereunder pertaining to ASU drugs but certain complaints received in the Ministry referred to these aspects. Two incidents of death have come to the notice of Ministry of AYUSH after consuming herbal medicines/products, one in Tamil Nadu and one in Kerala.


    In order to check the veracity of misleading advertisements and claims of AYUSH products, the Central Government has taken following steps-




    1. State Governments have been directed for appointing Gazetted Officers under section 8 (1) of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 to enter, search any premises or examine or seize any record which contravenes any provisions of the Act. About 621 Gazetted Officers for this purpose are reported to have been appointed in 22 states.

    2. Complaints of misleading advertisements of Ayurvedic, Siddha, Unani and Homoeopathic medicines are forwarded to the concerned State Licensing Authorities for action in accordance with the provisions of Drugs & Cosmetics Act, 1940 and Rules thereunder and Drugs & Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules thereunder. Out of the 809 complaints reflected on GAMA portal, about 274 complaints have been resolved and 585 complaints forwarded to concerned state authorities for appropriate action in accordance with the legal provisions. States have reported action taken by them against the defaulters.

    3. Ministry of AYUSH signed MoU with Advertising Standards Council of India (ASCI) to undertake monitoring of the misleading AYUSH –related advertisements appearing in print and TV media and bring the instances of improper advertisements to the notice of the State Regulatory Authorities for taking necessary action. ASCI reported that 233 alleged advertisements were rectified or withdrawn by the advertisers and about 456 complaints were escalated to the State regulators for appropriate action.

    4. On the request of Ministry of AYUSH, Ministry of Information & Broadcasting issued an advisory to all media channels to ensure strict compliance of the provisions of Drugs & Cosmetics Act, 1940 and Drugs & Magic Remedies (Objectionable Advertisements) Act, 1954 in respect of AYUSH health products/drugs being advertised. TV channels have been advised to advertise only those AYUSH products, which have valid manufacturing license.

    5. Provision of surveillance of AYUSH advertisements has been kept in the central scheme implemented for safety monitoring of Ayurvedic, Siddha, Unani and Homeopathy drugs under the pharmavigilance initiative.

    Advertising Standards Council of IndiaASCIAyurvedaAyush medicinesDepartment of Consumer AffairsDrugs and Cosmetics ActDrugs and Magic Remedies ActGAMAGrievances against Misleading Advertisementsherbal medicinesMinister of State for AYUSHMinistry of Ayushmisleading advertisementsRajya SabhaShripad Yesso NaikSiddhaUnani
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok